ARA-290 Research Spray Kit (12mg/7ml)

This item supplies ARA-290 as a research spray kit. ARA-290, also designated cibinetide, is an 11-residue peptide corresponding to a solvent-exposed face of the helix B domain of erythropoietin, designed to separate erythropoietin’s tissue-protective signalling from its haematopoietic activity.

The separation works because the two activities run through different receptors. Erythropoiesis requires the homodimeric EPO receptor; tissue protection is attributed to a heteromeric complex of the EPO receptor with the beta-common receptor, sometimes called the innate repair receptor. ARA-290 engages the latter without meaningful affinity for the former, so it does not raise haematocrit.

The kit presentation reflects how the peptide is handled rather than how it acts: the 12 mg vial is reconstituted with the supplied 7 ml solution and transferred to the amber 10 ml sprayer bottle. Working stability in the spray bottle is shorter than that of the sealed vial, so preparation volume should be matched to the protocol.

Findings below are drawn from published preclinical and clinical work and are presented for research context only.

• Receptor selectivity. The design rationale — tissue protection without erythropoiesis — is the compound's defining property and the reason it exists as a distinct research tool rather than a use of erythropoietin itself.

• Small-fibre neuropathy. Clinical investigation has concentrated on sarcoidosis-associated small-fibre neuropathy, with reported effects on corneal nerve fibre measures and on trial participant-reported neuropathic symptom scores.

• Inflammatory signalling. Preclinical work reports reduced pro-inflammatory cytokine production and altered macrophage phenotype, consistent with the innate repair receptor mechanism.

• Metabolic endpoints. Some studies have examined ARA-290 in metabolic and glycaemic contexts, extending the tissue-protection hypothesis beyond neural tissue.

• No haematocrit effect. Across studies, the absence of an erythropoietic response is a consistent and specifically reported finding rather than an assumption.

This section describes laboratory handling. It is not clinical guidance, and no safety claim for human or veterinary administration is made or implied.

• Reconstitute the 12 mg vial with the supplied 7 ml solution before transferring to the amber 10 ml sprayer bottle. Working stability in the spray bottle is shorter than that of the sealed vial; prepare only what the protocol requires.

• Handle as a research chemical of undetermined hazard. Use gloves, eye protection and a laboratory coat.

• Storage temperature and, where applicable, reconstitution conditions are stated on the item specification sheet and the lot Certificate of Analysis, which take precedence over general guidance.

• Dispose of unused material and consumables in accordance with the institutional chemical waste policy.

For laboratory research use only. Not for human or veterinary use. Not a drug, food, cosmetic or dietary supplement.

This kit supplies one 12 mg ARA-290 vial, one 7 ml reconstitution solution and one amber 10 ml sprayer bottle. ARA-290 is an 11-residue erythropoietin-derived peptide that engages the innate repair receptor complex while avoiding the homodimeric EPO receptor responsible for erythropoiesis.

The published record covers small-fibre neuropathy in sarcoidosis, inflammatory signalling in preclinical models, and metabolic endpoints. The consistent absence of a haematocrit response across studies is what makes the compound useful for isolating tissue-protective signalling.

Kit contents are supplied with a lot-specific Certificate of Analysis recording compound identity and measured purity.

1. Al-Onaizi MA, Thériault P, Lecordier S, Prefontaine P, Rivest S, ElAli A. Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain Behav Immun. 2022;99:363-382.

2. Yao M, Domogatskaya A, Ågren N, Watanabe M, Tokodai K, Brines M, et al. Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation. Cell Transplant. 2021;30:9636897211039739.

3. Yao M, Watanabe M, Sun S, Tokodai K, Cerami A, Brines M, et al. Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. Transplantation. 2020;104(10):2048-2058.

4. Lois N, Gardner E, McFarland M, Armstrong D, McNally C, Lavery NJ, et al. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. J Clin Med. 2020;9(7).

5. Bitto A, Irrera N, Pizzino G, Pallio G, Mannino F, Vaccaro M, et al. Activation of the EPOR-β common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes. Biochim Biophys Acta Mol Basis Dis. 2018;1864(2):632-639.

6. Nairz M, Haschka D, Dichtl S, Sonnweber T, Schroll A, Aßhoff M, et al. Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. Sci Rep. 2017;7(1):13012.

7. Culver DA, Dahan A, Bajorunas D, Jeziorska M, van Velzen M, Aarts LPHJ, et al. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Invest Ophthalmol Vis Sci. 2017;58(6):BIO52-BIO60.

8. Zhang W, Yu G, Zhang M. ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception. Peptides. 2016;76:73-9.